Clinical Trial Search

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Day 90. — -1.3; 2.7; 1.0; 3.3 ETDRS letters

Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE — 14; 13; 9; 17 Participants

Primary: Mean Symptom Severity Burden as Measured by MDASI Scores — 4.27; 4.26 score on a scale

Primary: Core Phase: Change From Baseline in Mean Actigraphy Sleep Efficiency (aSE) With Lemborexant Compared to Placebo During Week 1 of Treatment — 76.34; 77.64; 78.45; 76.38…

Primary: Overall Response Rate After Two Cycles of ROAD — 58 percentage of patients

Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events

Primary: Time to Prostate-specific Antigen (PSA) Progression — 7.3 Months

Primary: Change From Baseline to Day 28 in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4hrs) as Measured by Mixed-meal Tolerance Test…

Primary: Participants With Documented Complete Closure Of The Target Wound Within 1 Month After Initiation Of Treatment — 8; 6; 7; 7 Participants — p==0.3699

Primary: Change From Baseline in MRSA Sputum Density. — -0.25; -0.30; -0.63; 0.16 Log10 CFU/mL

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Tolerability and Safety Profile of UB-311 Assessed Via Recording of Number of Participants With Adverse Events — 10; 13; 13 Participants

Primary: Overall Survival (OS) at 6 Months — 7.9 months

Primary: Change in Tumor Volume — 10 Percent volume

Primary: Dose Responsiveness of BAF312 Based on the Number of Combined Unique Active MRI Lesions (CUAL) — 0.51; 0.83; 7.46 mg